Bioequivalence study of extended-release topiramate ( SPN-538) versus immediate-release topiramate at steady state.

Trial Profile

Bioequivalence study of extended-release topiramate ( SPN-538) versus immediate-release topiramate at steady state.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2016

At a glance

  • Drugs Topiramate (Primary) ; Topiramate (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 21 Apr 2015 Results of a pooled analysis of the negative effects of topiramate on verbal fluency in the IV/IR study (profile 700234568) and the SPN-538/IR study (profile 210651) were presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 06 Nov 2013 Cognitive function results will be presented at the Annual Meeting of the American Epilepsy Society (AES) in December 2013.
    • 08 Dec 2011 Primary endpoint of bioequivalence met as reported by results presented at the 65th Annual Meeting of the American Epilepsy Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top